Study: International, open-label, phase 3 trial Metastatic CRPC, previously treated with at least one androgen-receptor-pathway inhibitor and one or two taxane regimens 177Lu-PSMA-617 (7.4 GBq every 6 weeks for four
Study: Double-blind, randomized Phase II-III trial Untreated metastatic or unresectable melanoma Relatlimab and nivolumab vs nivolumab alone Efficacy: mPFS: 10.1 vs 4.6 mos (HR:0.75; P=0.006) 12 months PFS: 47.7% vs
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.